

VOLUME 77, 2004 KEYWORD INDEX

- Acetylcholine, 59, 337, 371
Acetylcholinesterase, 253
ACI rats, 281
Acoustic startle, 583
Acquisition rate, 77
Active avoidance, 77
Activity, 675, 731
Acute stress, 269
Addiction, 127
Adolescence, 21
Aggressiveness, 319
Agmatine, 345
Agouti mice, 117
Agression, 465
Alcohol effects, 647
Alcohol preference, 847
Allodynia, 695
Alstonine, 481
 γ -Aminobutyric acid, 761
 γ -aminobutyric acid/benzodiazepine system, 557
AMPA/kainate receptor antagonists, 85
Amphetamine, 319, 327, 471, 575
D-Amphetamine, 805
Amygdala, 447, 641
Analgesia, 517
Angiotensin II AT₁, AT₂ receptors, 667
Animal model, 767
Anoxia, 767
Antidepressant, 303
Antiepileptics, 227
Antinociception, 49
Antipsychotics, 481
Anxiety, 21, 221, 361, 405, 447, 481, 491, 567, 805
Anxiolytic agents, 847
Anxiolytic-like effect, 465
Anxiolytic screen, 221
apoE, 783
Apolipoprotein E, 783
Apomorphine, 291, 839
L-Arginine, 1, 111
Arginine vasopressin V₁ receptors, 667
Associative learning, 191
Atypical antipsychotics, 163
Audiogenic seizures, 85, 227
Auditory P300, 103
Autoshaping, 797
Aversion, 731
Baboon, 471
Behavior, 319, 491, 647
Behavioral sensitization, 823
Behaviour, 163, 303, 751
Behavioural neurotoxicity, 805
Behavioural sensitisation, 815
Benzodiazepines, 77
2,3-Benzodiazepines, 85
Body shakes, 623
BP897, 309
Brain, 253
Brain damage, 381
Brain slice, 595
Brain targeting, 423
Brain temperature, 823
1,4-Butanediol, 705
 γ -Butyrolactone, 705
Butyrylcholinesterase, 253
CA1, 595
Cannabinoid, 117
Cannabinoid agonist, 567
Carbohydrate, 137
Carbon dioxide, 39
Carbon monoxide, 685
Cardiovascular balance, 667
Carrageenan, 695
Castration, 9, 423
C57BL/6J, 783
Central nervous system, 751
Central vs. peripheral effect, 423
Cerebral ischemia, 607
Cerebral metabolism, 175
CFM-2, 85
c-fos, 447
Chemoconvulsions, 85
Choline acetyltransferase, 59
Cholinergic drugs, 525
Cholinesterase inhibitors, 337
Cigarette, 29
Cigarette smoking, 793
Cigarette smoking compensation, 685
Citalopram enantiomers, 391
Classical conditioning, 567
Clozapine, 163, 199
Club drugs, 705
CNS, 399
Cocaine, 127, 235, 525, 775, 783, 805, 823
Cognition, 547
Cognitive function, 675
Combined exposure, 253
Conditioned place preference, 49, 235, 327, 783
Conditioned taste aversion, 655
Convulsants, 761
Convulsion, 345
Convulsions, 1, 509, 775
Copulatory behavior, 423
Core body temperature, 365
Corticosterone, 391, 447
Corticotropin-releasing factor, 465
Corticotropin-releasing factor (CRF), 855
Cotinine, 685
CP-154,526, 405
CP 55,940, 567
CP-154,526, 855
CRA1000, 405
CRF, 405
CRF₁ receptor, 855
CRF₁ receptors, 405
Cutaneous circulation, 351
Cyclazocine, 711
Cytochrome oxidase, 175
D2/3 agonist, 309
D2/3 antagonist, 309
Database, 655
DBA/2 mice, 85
DEET, 253
Dehydroepiandrosterone, 601
Dependence, 327
Depression, 15
Deprivation, 471
Dessert test, 541
Development, 491
Developmental, 127

- Dexfenfluramine, 471
 Diarrhea, 337
 Diazepam, 361, 471
 Diisopropyl fluorophosphate, DFP, 337
 Diphenylhydantoin, 657
 Diuresis, 49
 DOI, 623
 Domestic fowl, 221
 Dominance, 583
 Donepezil, 337
 Dopamine, 245, 291, 327, 415, 431, 745, 767
 Dopaminergic pathways, 751
 Drug discrimination, 163, 199
 Drugs of abuse, 647
 DSIP, 227
 DSIP(1-4), 227
 DSP-4, 855
 DT-diaphorase, 245

 Ecstasy, 805
 EEG, 103
 Elderly, 209
 Electrolytic, 667
 Elevated plus maze, 21, 281
 Elevated plus-maze, 805, 361
 Epilepsy, 85, 509, 761
 Erythropoietin, 381
 Eserine, 275
 Estradiol, 423
 Estrous cycle, 155
 Ethanol, 731, 783, 797, 805, 815
 Ethnicity, 685
 Evoked cortical responses, 95
 Excitatory amino acid, 761
 Excitatory amino acids, 95
 Exercise, 49
 Exploratory activity, 145
 Exploratory behaviour, 855

 Fast onset, 69
 Fatigue, 547
 Fawn-hooded rats, 281
 Fear, 557
 Female sexual behavior, 431
 Fenfluramine, 351
 Fimbria–fornix, 381
 Fischer-344, 209
 FK506, 607
 Flash-evoked potentials, 717
 Flavonoids, 399
 Flinders rats, 337
 Fluoxetine, 9, 69
 Flutamide, 9
 Food avoidance, 655
 Food consumption, 675

 Food intake, 117, 137, 471
 Forced swim, 15
 Forced swim test, 303
 Forced swimming test, 457
 Formalin test, 9
 Fos immunoreactivity, 541
 Freezing, 557
 Functional observational battery procedure, 847
 Functional recovery, 381

 Genetic polymorphisms, 793
 Genetics, 647
 Genital reflexes, 525
Ginkgo biloba, 533
 Glucosamine–kynurenic acid, 95
 Glutamate, 15, 191, 345, 481, 501, 641
 Glutathione S-transferase, 793
 GM1 gangliosides, 509
 GR 127935, 69
 GYKI 52466, 85
 GYKI 53655, 85
 GYKI 53773, 85

 Haloperidol, 199
 Head bobs, 623
 Heroin, 805
 L-[³H]Glutamate uptake, 601
 Hippocampus, 209, 381, 595
 Hole-board, 481
 Holeboard maze, 175
 Homocysteine metabolism, 269
 HPLC, 575
 5-HT₃, 415
 5-HT_{2A} receptors, 623
 5-HT_{2C} receptors, 623
 5-HT₃ receptor, 281
 Hydromorphone, 263, 711
 γ -Hydroxybutyrate, 705
 5-Hydroxy-L-tryptophan, 137
 5-Hydroxytryptophan potentiation, 391
 Hyperactivity, 745
 Hyperalgesia, 631, 695
 Hypercapnia, 39
 Hyperthermia, 365
 Hypoactivity, 337
 Hypothermia, 337, 351, 705, 717

 Immunocytochemistry, 415
 Incision, 695
 Inflammation, 145, 631
 Inhalation, 361
 In situ hybridization, 209
 Interleukin-6, 761
 Intracerebroventricular, 623

 Kappa, 49
 Kappa opioid agonist, 711
 Ketanserin, 623
 α -Ketoisocaproic acid, 183
 α -Ketoisovaleric acid, 183
 α -Keto- β -methylvaleric acid, 183
 Knockout mice, 783
 Kynurenic acid, 95

 Laboratory paradigm, 29
 Larval zebrafish, 647
 Lead, 127
 Learning, 59, 533
 Learning and memory, 607
 Light/dark, 481
 Linarin, 399
 Lipopolysaccharide, 365
 Locomotion, 21, 501, 517, 717
 Locomotor, 309
 Locomotor activity, 49, 647, 705, 783, 815
 Locomotor sensitization, 617
 Locus coeruleus (LC), 855
 Long-term memory, 191
 Lordosis, 431
 Lordosis behavior, 423

 M100907, 199
 Major depression, 155
 Manganese, 245
 Maple syrup urine disease, 183
 Maximal electroshock, 85, 345
 MDL 72222, 281
 MDMA, 745, 805
 Mechanical, 695
 Medial prefrontal cortex, 371
 Melatonin, 275
 Melperone, 199
 Memantine, 191
 Memory, 59, 583
 Memory formation, 1
 Memory retention, 175
 Metaphit, 227
 Methadone, 39
 Methamphetamine, 319, 365
 Methylene blue, 175
 Methylphenidate, 491
 Mice, 235, 309, 365, 391, 457, 481, 491
 Microdialysis, 371, 501
 Midazolam, 77
 Mitochondria, 175
 MK-801, 191
 MK801, 309
 MK-801, 641

- m2 muscarinic acetylcholine receptor, 253
 Modafinil, 547
 Monoamine neurochemistry, 855
 Morphine, 111, 235, 263, 327, 695
 Morphine tolerance, 517
 Motivation, 471
 Motor activity, 365, 575
 Motor coordination, 583
 Mouse, 501
 Mouse-killing behavior, 641
 Mushroom bodies, 191

N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolines, 85
N-acetylaspartate, 767
 NADH, 303
 Nafadotride, 309
 Na⁺/K⁺-ATPase, 657
 Naloxone, 263
 Naltrexone, 29
 L-NAME, 111
 NBQX, 85
 Nefopam, 695
 Neural activation, 823
 Neurodegeneration, 245, 607
 Neurodegenerative diseases, 175
 Neuronal protection, 95
 Neuroprotection, 381, 607
 Neurotransmitter levels, 675
 Neurotrophic effects, 381
 Neurotrophin, 209
 Nicotine, 21, 39, 717, 815
 Nicotinic acetylcholine receptor, 253
 Nitric oxide, 1, 111, 457
 Nitric oxide CNS, 667
 Nitric oxide synthase, 1
 7-Nitroindazole, 1
 NMDA receptor, 345, 641
 Nociception, 145
 Nucleus accumbens, 327
 Nucleus basalis of Meynert, 59

 Obesity, 117
ob/ob mice, 117
 (+)-8-OH-DPAT, 199
 Olfactory bulbectomy, 641
 Open field, 575
 Opiate, 327
 Opiates, 509
 Opioid, 49, 263
 Opioid antagonist, 29
 Opioid dependence, 39
 Oral intake, 815
 Oxygen consumption, 175, 351

 Pacing, 431
 Pain, 145, 275, 631
 Pancreatitis, 631
 Panic attacks, 557
 Paradoxical sleep deprivation, 525
 Parkinsonism, 245
 Passive avoidance, 59
Pavetta crassipes, 751
 Pavlovian, 797
p-Chloroamphetamine, 59
 Periaqueductal gray matter, 557
 Permethrin, 253
 Persian Gulf War, 253
 Phencyclidine, 291
 Physical activity, 209
 Physical dependence, 263
 Physostigmine, 59
 Picrotoxin, 1
 Place conditioning, 731, 783
 Place learning, 381
 Plasticity, 381
 Play behavior, 583
 Polydrug use, 711
 Potassium channels, 457
 Potentiation, 399, 695
 Power spectra, 227
 Precipitated withdrawal, 263
 Preference, 731, 797
 Prenatal, 491
 Prenatal drug exposure, 509
 Prepulse inhibition, 291, 583, 767, 839
 Presynaptic, 617
 Proboscis conditioning, 191
 Propofol, 595
 Protein, 137
 Pseudoconditioning, 797
 Psychological stress, 269
 Psychomotor, 309
 Psychostimulant, 319, 327
 Pyridostigmine bromide, 253

 Quetiapine, 163
 Quinpirole, 617

 Rabbit, 623
 Radial maze, 607
 Rat, 49, 77, 95, 199, 275, 303, 381, 391, 525, 815
 Rat behavior, 183
 Rat brain, 575
 Rats, 163, 269, 361, 717, 731, 797, 823
 σ Receptor, 775
 Reinforcing properties, 235
 Repeated ethanol withdrawal, 405
 Respiratory depression, 39
 Retention, 797

 Retrieval, 77
 Rodent, 491
 Rose oil, 361
 Running wheels, 117

 Sarin, 337
 SCH 23390, 745
 Schedule-induced polydipsia, 69
 Schizophrenia, 371, 767
 Schizophrenia startle, 291
 Scopolamine, 337
 Sedation, 399
 Seizures, 761
 Selected rat lines, 847
 Self-administration, 111, 127, 235, 745
 Sensitization, 415
 Sensorimotor, 253
 Sensorimotor gating, 839
 Separation stress, 221
 Serine, 501
 Serotonin, 59, 137, 351, 415, 481, 557
 Sertraline, 457
 Serum concentration, 391
 Sex, 155
 Sex differences, 517
 Sexual-incentive motivation, 431
 Shell, 415
 Signal transduction, 145
 Sleep, 751
 Sleep-enhancing properties, 399
 Sleepiness, 547
 Smoking, 29, 711
 Social experience, 235
 Social interaction, 319, 447
 Social interaction test, 405, 567
 Social isolation, 371
 Soman, 337
 Spatial learning, 583
 Spatial memory, 175
 Species difference, 541
 Spectral analysis, 103
 Spinal cord, 275
 Spiradoline, 49
 Spontaneous and evoked bursting, 595
 Spontaneously hypertensive, 583
 Sprague–Dawley, 21, 209
 SR 141716, 839
 SSRI, 69
 Startle response, 839
 Stereotypy, 501
 Strain, 291
 Stress, 15, 155, 447
 Stressor, 509
 Striatum, 501
 Subjective effects, 29
 Substance abuse, 319

- Substance P, 631
Superior colliculus, 717
Sympathetic nervous system, 351
Synaptosomal glutamate release, 601
Synaptosome, 541
- Tactile, 695
Telemetry, 365
THC, 675
Thermal, 695
Thermoregulation, 351
Tiazofurin, 575
Tobacco smoking, 39
- Tolerance, 541
Topography, 685
Transcription factor AP-2, 855
Tranlycypromine, 209
Trihexyphenidyl, 199
- Valerenic acid, 399
Valeriana, 399
Validation, 221
Ventilatory response, 39
Veratridine, 595
Visual cortex, 717
Visual-evoked potentials, 717
- Wakefulness, 547
Water maze, 381, 533
WAY 100635, 69
Weak training experience, 657
Weight loss, 675
Windup, 275
Wistar–Kyoto, 583
Withdrawal syndrome, 327
- Xylamidine, 623
Zotepine, 163